Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 1;114(5):2098–2108. doi: 10.1111/cas.15746

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Overall survival (OS) and impact for death of the analysis cohort of AML patients. (A) Survival curves for newly diagnosed unfit AML and relapsed or refractory (R/R) AML. (B) Survival analysis with or without stem cell transplantation (SCT) in relapsed or refractory AML. Log–rank test was used in survival time analysis. (C) OS, hazard ratio (HR) of death by each mutation. Multivariable Cox proportional hazards regression model was used to estimate the effect of various predictor variables. *p < 0.05; **p < 0.01; ***p < 0.001. (D) Survival analysis according to TP53 valiant allele frequency (VAF). Log–rank test was used in survival time analysis. CI, confidence interval; mo, months; mOS, median overall survival; NR, not reached.